Results 11 to 20 of about 295,380 (280)

Atypical burkitt's lymphoma transforming from follicular lymphoma [PDF]

open access: yesDiagnostic Pathology, 2011
Amongst follicular lymphoma that transforms into a high-grade lymphoma, majority are diffuse large B cell lymphoma. Here we reported a rare atypical Burkitt's lymphoma transformation from an asymptomatic follicular lymphoma.
Chung Lap P   +3 more
doaj   +2 more sources

Smad1 Expression in Follicular Lymphoma [PDF]

open access: yesJournal of Pathology and Translational Medicine, 2015
Background: Follicular lymphomas present with various immunohistologic patterns. The immunohistochemical markers used in the diagnosis of follicular lymphoma show variable degrees of sensitivity and specificity, and thus, additional germinal center ...
Jai Hyang Go
doaj   +2 more sources

Dissecting the gray zone between follicular lymphoma and marginal zone lymphoma using morphological and genetic features [PDF]

open access: yesHaematologica, 2013
Nodal marginal zone lymphoma is a poorly defined entity in the World Health Organization classification, based largely on criteria of exclusion and the diagnosis often remains subjective.
Oscar Krijgsman   +12 more
doaj   +2 more sources

Nature and importance of follicular lymphoma precursors [PDF]

open access: yesHaematologica, 2014
It is now widely recognized that cancer development is a protracted process requiring the stepwise acquisition of multiple oncogenic events. In humans, this process can take decades, if not a lifetime, blurring the notion of ‘healthy’ individuals ...
Emilie Mamessier   +6 more
doaj   +2 more sources

Follicular Lymphoma Presenting with Leptomeningeal Disease [PDF]

open access: yesCase Reports in Hematology, 2014
Follicular lymphoma is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Central nervous system metastasis is a very rare complication portending a very poor prognosis. We report a rare case of follicular
Rubens Costa   +2 more
doaj   +2 more sources

DNA methylation in follicular lymphoma [PDF]

open access: yes, 2010
PhDFollicular Lymphoma (FL) is a common B cell Non-Hodgkin Lymphoma with a median survival of 8-10 years. Patients frequently undergo transformation to a more aggressive lymphoma and this is associated with drastically reduced survival.
Ó Riain, Ciarán Liam
core   +4 more sources

The impact of molecular alterations and the immune microenvironment on the natural history of Follicular Lymphoma including transformation to Diffuse Large B cell Lymphoma [PDF]

open access: yes, 2009
PhDThe natural history of follicular lymphoma is heterogeneous with numerous relapses and remissions over many years. A substantial number of patients suffer an aggressive disease course with death due to disease within 5 years of diagnosis.
Lee, Abigail Mary
core   +4 more sources

Molecular mechanisms of follicular lymphoma and its transformation [PDF]

open access: yes, 2011
PhDFollicular lymphoma (FL) is the second most common form of non-Hodgkin lymphoma and at least a third of cases undergo aggressive transformation (t-FL), most frequently to diffuse large B-cell lymphoma.
Wrench, David John
core   +4 more sources

Early lesions of follicular lymphoma: a genetic perspective

open access: yesHaematologica, 2014
The pathogenesis of follicular lymphoma is a multi-hit process progressing over many years through the accumulation of numerous genetic alterations. Besides the hallmark t(14;18), it is still unclear which other oncogenic hits contribute to the early ...
Emilie Mamessier   +14 more
doaj   +1 more source

Lenalidomide in follicular lymphoma [PDF]

open access: yesBlood, 2020
Abstract Lenalidomide is an immunomodulatory drug approved in the United States for use with rituximab in patients with relapsed/refractory follicular lymphoma. We reviewed data from trials addressing the safety and efficacy of lenalidomide alone and in combination with rituximab as a first-line therapy and as a treatment of patients ...
Christopher R, Flowers   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy